Plants are provided with increased ribulose-1,5-bisphosphate (RuBP) regeneration capacity during the Calvin cycle through increased expression of sedoheptulose 1,7 bisphosphatase, in combination with reduced photo-respiratory losses through expression of glycolate catabolizing enzymes. Such plants have a greater growth rate and/or improved biomass and/or increased carbon fixation compared to untreated plants, or plants comprising only one of the features above.

Described are recombinant microorganisms characterized by having phosphoketolase activity, having a diminished or inactivated Embden-Meyerhof-Parnas pathway (EMPP) by inactivation of the gene(s) encoding phosphofructokinase or by reducing phosphofructokinase activity as compared to a non-modified microorganism and having a diminished or inactivated oxidative branch of the pentose phosphate pathway (PPP) by inactivation of the gene(s) encoding glucose-6-phosphate dehydrogenase or by reducing glucose-6-phosphate dehydrogenase activity as compared to a non-modified microorganism. These microorganisms can be used for the production of useful metabolites such as acetone, isobutene or propene.

The present invention provides an engineered cyanobacterium, comprising at least one plasmid selected from three novel pathways to produce acetate, which can convert atmospheric carbon dioxide as a raw material into acetate. The present invention also constructs the expression plasmid for three different transporters specific to acetate to be expressed in cyanobacteria, which comprises putative ABC transporter (AatA), succinate/acetate: proton symporter (SatP) and acetate/glycolate: cation symporter (ActP). Therefore, the engineered cyanobacteria of the present invention can produce 0.58 mg/L to 3.54 mg/L of acetate per hour.

The present disclosure relates to a dry chloroplast composition comprising chloroplasts isolated from Fabaceae family plants. The composition has a moisture content of less than about 8%. The composition has at least one ratio chosen from: a ratio of chlorophyll/fructose 1,6-biphosphatase (FBPP) of about 50 to about 130, the ratio of chlorophyll/FBPP being

[00001]$\frac{\mathrm{chlorophyll}\mathrm{in}\left(\mathrm{mg}/g\right)}{\mathrm{FBPP}\mathrm{in}\left(\mathrm{intensity}/\mathrm{mg}\mathrm{powder}\right)}?10000000,$ The FBPP intensity being measured by immunoblot, a ratio of Rubisco/chlorophyll of about 25 to about 65, the ratio of Rubisco/chlorophyll being

[00002]$\left(\frac{Ru\mathrm{bisco}\mathrm{in}\mathrm{intensity}}{chloro\mathrm{phyll}\mathrm{in}\left(\mathrm{mg}/g\right)}\right)/1000,$ wherein the Rubisco intensity being measured by immunoblot, a ratio of Rubisco/chlorophyll of about 2.5 ng/mg to about 6.5 ng/mg, the ratio of Rubisco/chlorophyll being

[00003]$ ( R u bisco in ng / mg powder c h l o r o phyll in ( mg / g ) ) / 1000< ENZYMATIC PRODUCTION OF HEXOSES 20240352440 · 2024-10-24 · BONUMOSE, INC. · Daniel Joseph WICHELECKI, Edwin O. Rogers Disclosed herein are methods of producing hexoses from saccharides by enzymatic processes. The methods utilize fructose 6-phosphate and at least one enzymatic step to convert it to a hexose. Engineered microorganisms with G3P → 3PG enzyme and/or fructose-1,6-bisphosphatase including those having synthetic or enhanced methylotrophy 12234463 · 2025-02-25 · Genomatica, Inc. · Harish Nagarajan, Tae Hoon Yang, Ali Khodayari Described herein are engineered cells including ones having synthetic methylotrophy which include an NADH-dependent enzyme capable of converting G3P to 3PG (e.g., B. methanolicus gapN) and/or fructose-1,6-bisphosphatase, along with hexulose-6-phosphate synthase, 6-phospho-3-hexuloisomerase, a phosphoketolase, or a combination thereof. Engineered cells of the disclosure beneficially maintain adequate pool sizes of phosphorylated C3 and/or C4 compounds, and/or provide increased levels of NADPH. As such, the modifications allow for the generation of C6 compounds from C1 (e.g., a methanol feedstod) and C5 compounds, the regeneration of C5 compounds from C6 compounds by carbon rearrangement, and an improved balance between regeneration of C5 compounds and lower glycolysis. In turn, this allows the engineered microorganism to generate sufficient quantities of metabolic precursors (e.g., acetyl-CoA) which can be used in a bioproduct pathway, and the engineered cells can include further modifications to those pathway enzymes allowing for production of a desired bioproduct. Methods for inhibiting starvation of a cell 09610363 · 2017-04-04 · President And Fellows Of Harvard College · Constance L. Cepko, Claudio Punzo The present invention is directed to methods for the treatment or prevention of starvation in a cell, e.g., a neuronal cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which enhances the intracellular generation and/or uptake of glucose, pyruvate, lactate, and/or NADPH. METHOD FOR CONSTRUCTING THREONINE-PRODUCING ENGINEERED BACTERIUM 20250122510 · 2025-04-17 · Pei KANG, Weibo GONG, Jun HE, Yan LI The present invention provides a method for constructing a threonine-producing engineered bacterium. According to the present invention, a 2-methylcitrate synthase 1-inactivated strain (Corynebacterium) is applied to the production of threonine, and the production of threonine produced by the 2-methylcitrate synthase 1-inactivated strain is increased by about 42% compared with that produced by an unengineered strain. When the application of the 2-methylcitrate synthase 1-inactivated strain is further combined with enhanced expression of at least one of aspartate aminotransferase, aspartate kinase, homoserine dehydrogenase, threonine synthase, NAD kinase, fructose-1,6-bisphosphatase 2 and the like in the threonine synthesis pathway, the production of threonine is improved. The method provides a new way for large-scale production of threonine and has high application value. Fermentative production of oligosaccharides by total fermentation utilizing a mixed feedstock 12338473 · 2025-06-24 · Chr. Hansen A/S · Stefan Jennewein, Dirk Wartenberg, Katja Parschat Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells. Multifunctional Multispecific Multimeric Biomolecule Polymer Having Prolonged In-Vivo Duration 20250250321 · 2025-08-07 · ONEGENE BIOTECHNOLOGY INC. · Sungjin PARK, Daeseong Im, Ryuryun Kim, Minsum Kim, Jaeyoung CHOI The present invention provides a multifunctional multispecific multimeric biomolecule polymer which is formed by obtaining a biomolecule, to which a ubiquitin C-terminal tag is bound, by recombinantly expressing the biomolecule from a host cell, and polyubiquitinating, in vitro, the biomolecule along with a substrate, and proteins E1 (activation enzyme), E2 (conjugation enzyme) and E3 (ligase) which are involved in ubiquitination, and thus having the biomolecule bind to a polyubiquitin scaffold which is formed by covalently bonding two or more ubiquitins. The biomolecule of the present invention may be one or more selected from the group consisting of a protein, peptide, polypeptide, antibody, antibody fragment, DNA and RNA, and, for example, by using heterologous proteins, modularized functionality may be imparted to the multifunctional multispecific biomolecule polymer. In addition, according to the present invention, the multifunctional multispecific multimeric biomolecule polymer is provided in a form that is bound to a molecule capable of increasing the in vivo duration, and thus may be used for producing drugs requiring the increased in vivo duration of efficacy. $